Design, synthesis and biological evaluation of novel azaspiro analogs of linezolid as antibacterial and antitubercular agents

European Journal of Medicinal Chemistry

Volumn 122, Issue , 2016, Pages 475-487

  Gadekar, Pradip K ^a   Roychowdhury, Abhijit ^a   Kharkar, Prashant S ^b   Khedkar, Vijay M ^c,d   Arkile, Manisha ^c   Manek, Hardik ^c   Sarkar, Dhiman ^c   Sharma, Rajiv ^a   Vijayakumar, V ^e   Sarveswari, S ^e  

^a Piramal Enterprises Limited   (India)

^b SVKM s Narsee Monjee Institute of Management Studies   (India)

^c NATIONAL CHEMICAL LABORATORY   (India)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e VIT UNIVERSITY   (India)

Author keywords

Antibacterial; Antitubercular; Azaspiro; Bioisostere; Morpholine; MRSA (methicillin resistant Staphylococcus aureus); VRE (vancomycin resistant enterococci)

Indexed keywords

1 (4 CHLOROPHENYL) 3 [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL]THIOUREA; 1 (4 CHLOROPHENYL) 3 [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL]UREA; 1 (CYANOPHENYL) [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL]THIOUREA; 1 (TERT BUTYL) 3 [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL]THIOUREA; 1 BENZYL 3 [[(3 FLUORO 4 MORPHOLINOPHENYL)AMINO]METHYL]PYRROLIDIN 3 OL; 1 [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL] 3 (2 FLUOROPHENYL)THIOUREA; 1 [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL] 3 (2 FLUOROPHENYL)UREA; 1 [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL] 3 (4 FLUOROPHENYL)UREA; 1 [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL] 3 (4 METHOXYPHENYL)THIOUREA; 1 [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL] 3 (4 NITROPHENYL)THIOUREA; 1 [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL] 3 ISOPROPYLTHIOUREA; 1 [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL] 3 [3 (TRIFLUOROMETHYL)PHENYL]THIOUREA; 1 [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL] 3 [3 (TRIFLUOROMETHYL)PHENYL]UREA; 2 CHLORO N [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL] 5 NITROBENZENESULFONAMIDE; 3 (3 FLUORO 4 MORPHOLINOPHENYL) 1 OXA 3,7 DIAZASPIRO[4.4]NONAN 2 ONE; 3,5 DICHLORO N [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL]BENZENESULFONAMIDE; 5 BENZYL 1 OXA 5 AZASPIRO[2.4]HEPTANES; 5 CHLORO N [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL]THIOPHENE 2 SULFONAMIDE; 7 ACETYL 3 (3 FLUORO 4 MORPHOLINOPHENYL) 1 OXA 3,7 DIAZASPIRO[4.4]NONAN 2 ONE; 7 BENZYL 3 (3 FLUORO 4 MORPHOLINOPHENYL) 1 OXA 3,7 DIAZASPIRO[4.4]NONAN 2 ONE; ANTIBIOTIC AGENT; LINEZOLID; N [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL] 1,2 DIMETHYL 1H IMIDAZOLE SULFONAMIDE; N [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL] 2 METHOXYACETAMIDE; N [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL] 3 (TRIFLUOROMETHYL)BENZENESULFONAMIDE; N [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL] 4,7,7 TRIMETHYL 3 OXO 2 OXABICYCLO[2.2.1]HEPTANE 1 CARBOXAMIDE; N [[3 [3 FLUORO 4 (2 OXA 6 AZASPIRO[3.3]HEPTAN 6 YL)PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL]ADAMANTANE 1 CARBOXAMIDE; TERT BUTYL 3 [4 [5 (ACETAMIDOMETHYL) 2 OXOOXAZOLIDIN 3 YL] 2 FLUOROPHENYL] 8 AZABICYCLO[3.2.1]OCT 2 ENE 8 CARBOXYLATE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; SPIRO COMPOUND;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; COMPUTER MODEL; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IC50; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; CHEMISTRY; COMPUTER SIMULATION; MICROBIAL SENSITIVITY TEST; SYNTHESIS;

ANTITUBERCULAR AGENTS; CHEMISTRY TECHNIQUES, SYNTHETIC; COMPUTER SIMULATION; DRUG DESIGN; LINEZOLID; MICROBIAL SENSITIVITY TESTS; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84978218277     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.07.001     Document Type: Article

References (24)

1. [1] Gilbert, D.N., Guidos, R.J., Boucher, H.W., Talbot, G.H., Spellberg, B., Edwards, J.E. Jr., Scheld, W.M., Bradley, J.S., Bartlett, J.G., Infectious diseases society of America, the 10 X 20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 50 (2010), 2081–2083.
2. [2] Katarzyna, M., Izabela, K., Marek, K., Stefan, T., Recent development of potent analogues of oxazolidinone antibacterial agents. Bioorg. Med. Chem. Lett. 21 (2013), 577–591.
3. [3] Yong, S.P., Smith, P.W., Diagana, T.T., Therapeutics for neglected infectious diseases: progress and challenge. ACS Infect. Dis. 1 (2015), 76–78.
4. [4] Becerra, M.C., Bayona, J., Freeman, J., Farmer, P.E., Kim, J.Y., Redefining MDR-TB transmission ‘hot spots’. Int. J. Tuberc. Lung Dis. 4 (2000), 387–394.
5. [5] Berry, M., Kon, O.M., Multidrug and extensively drug-resistant tuberculosis: an emerging threat. Eur. Respir. Rev. 18 (2009), 195–197.
6. [6] Cardona, P.J., Ruiz-Manzano, J., On the nature of Mycobacterium tuberculosis-latent bacilli. Eur. Respir. J. 24 (2004), 1044–1051.
7. [7] Wayne, L.G., Dormancy of Mycobacterium tuberculosis and latency of disease. Eur. J. Clin. Microbiol. Infect. Dis. 13 (1994), 908–914.
8. [8] Locht, C., Rouanet, C., Hougardy, J.M., Mascart, F., How a different look at latency can help to develop novel diagnostics and vaccines against tuberculosis. Expert. Opin. Biol. Ther. 7 (2007), 1665–1677.
9. [9] W.A. Greory, D. Wilmington, P-oxooxazoliidinylbenzene compounds as antibacterial agents. U. S. Patent 4, 461,773, 1984.
10. [10] De Rosa, M., Zanfardino, A., Notomista, E., Wichelhaus, T.A., Saturnino, C., Varcamonti, M., Soriente, A., Novel promising linezolid analogues: rational design, synthesis and biological evaluation. Eur. J. Med. Chem. 69 (2013), 779–785.
11. [11] Dover, L.G., Coxon, G.D., Current status and research strategies in tuberculosis drug development. J. Med. Chem. 54 (2011), 6157–6165.
12. [12]a) Naresh, A., Venkateswara Rao, M., Kotapalli, S.S., Ummanni, R., Venkateswara Rao, B., Oxazolidinone derivatives: cytoxazone-linezolid hybrids induces apoptosis and senescence in DU145 prostate cancer cells. Eur. J. Med. Chem. 80 (2014), 295–307.
13. [12]b) Ippolito, J.A., Kanyo, Z.F., Wang, D., Franceschi, F.J., Moore, P.B., Steitz, T.A., Duffy, E.M., Crystal structure of oxazolidinone antibiotic linezolid bound to 50S ribosomal subunit. J. Med. Chem. 51 (2008), 3353–3356.
14. [13] Leach, L.K., Swaney, S.M., Colca, J.R., McDonald, W.G., Blinn, J.R., Thomasco, L.M., Gadwood, R.C., Shinabarger, D., Xiong, L., Mankin, A.S., The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol. Cell 26 (2007), 393–402.
15. [14] Tsiodras, S., Gold, H.S., Sakoulas, G., Eliopoulos, G.M., Wennersten, C., Venkataraman, L., Moellering, R.C., Ferraro, M.J., Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358 (2001), 207–208.
16. [15] Gonzales, R.D., Schreckenberger, P.C., Graham, M.B., Kelkar, S., Besten, K.D., Quinn, J.P., Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet, 357, 2001, 1179.
17. [16] McKillop, D., McCormick, A.D., Miles, G.S., Phillips, P.J., Pickup, K.J., Bushby, N., Hutchison, M., In vitro metabolism of gefitinib in human liver microsomes. Xenobiotica 34 (2004), 983–1000.
18. [17] Balani, S.K., itzenberger, S.M.P., Schwartz, M.S., Ramjit, H.G., Thompson, W.J., Metabolism of L-689,502 by rat liver slices to potent HIV-1 protease inhibitors. Drug Metab. Dispos. 23 (1995), 185–189.
19. [18] Giraldi, P.N., Tosolini, G.P., Dradi, E., Nannini, G., Longo, R., Meinardi, G., Monti, G., de Carneri, L., Biochempharmacol. 20 (1971), 339–349.
20. [19] Wuitschik, G., Carreira, E.M., Wagner, B., Fischer, H., Parrilla, I., Schuler, F., Evans, R.M., Müller, K., Oxetanes in drug discovery: structural and synthetic insights. J. Med. Chem. 53 (2010), 3227–3246.
21. [20] Wuitschik, G., Evans, R.M., Müller, K., Fischer, H., Wagner, B., Schuler, F., Polonchuk, L., Carreira, E.M., Oxetanes as promising modules in drug discovery. Angew. Chem. Int. Ed. 459 (2006), 7736–7739.
22. [21] Kitani, H., Kuroda, T., Moriguchi, A., Ao, H., Hirayama, F., Ikeda, Y., Kawakita, T., Synthesis and structural optimization of 7-(3,3-[d]-1-substituted-1-pyrrolidinyl)-1-cyclopropyl-6- fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acids as antibacterial agents. Bioorg. Med. Chem. Lett. 7 (1997), 515–520.
23. [22] Singh, U., Akhtar, S., Mishra, A., Sarkar, D.A., Novel screening method based on menadione mediated rapid reduction of tetrazolium salt for testing of anti-mycobacterial agents. J. Micro. Methods 84 (2011), 202–207.
24. [23] Khan, A., Sarkar, D.A., Simple whole cell based high throughput screening protocol using Mycobacterium bovis BCG for inhibitors against dormant and active tubercle bacilli. J. Micro. Methods 73 (2008), 62–68.